Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    KDDr. Kelly Dooley
    Leading Voice

    Dr. Kelly Dooley

    Infectious Disease · Mycobacterial Disease
    Vanderbilt Health
    kelly

    Research

    MAC complex (MAC) elimination slopes from sputum are potential treatment response biomarkers in patients with HIV and pulmonary MAC

    2026

    Via IJTLD Open

    Research

    Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis

    2026

    Via The European Respiratory Journal

    Apr 30, 2026Journal Article

    Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

    ​

    Written by 1 Roon author & 11 others

    Via Clinical Infectious Diseases

    Research

    REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENT

    2025

    Via Transactions of the American Clinical and Climatological Association

    Research

    Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

    2025

    Via Emerging Infectious Diseases

    Research

    Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

    2025

    Via International Journal of Antimicrobial Agents

    Research

    Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID)

    2025

    Via The Lancet. HIV

    Research

    Tuberculosis disease among people with HIV: therapeutic advances

    2025

    Via The Lancet. HIV

    Research

    Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis

    2025

    Via Pharmacogenetics and Genomics

    Research

    Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV

    2025

    Via The Lancet. HIV

    Research

    ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis

    2025

    Via Trials

    Research

    Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design

    2025

    Via Contemporary Clinical Trials

    Research

    Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016–2020

    2025

    Via Emerging Infectious Diseases

    Dec 24, 2025Journal Article

    A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis.

    ​

    Written by 1 Roon author & 12 others

    Via Clinical Infectious Diseases

    Research

    Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study)

    2025

    Via The Lancet. HIV